These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 9265937

  • 1. Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
    Korttila K, Clergue F, Leeser J, Feiss P, Olthoff D, Payeur-Michel C, Wessel P, Nave S, Hahne W, Brown R.
    Acta Anaesthesiol Scand; 1997 Aug; 41(7):914-22. PubMed ID: 9265937
    [Abstract] [Full Text] [Related]

  • 2. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W.
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [Abstract] [Full Text] [Related]

  • 3. Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery.
    Diemunsch P, D'Hollander A, Paxton L, Schoeffler P, Wessel P, Navé S, Brown RA, Hahne WF.
    J Clin Anesth; 1997 Aug; 9(5):365-73. PubMed ID: 9257201
    [Abstract] [Full Text] [Related]

  • 4. Oral dolasetron mesylate for prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. The Oral Dolasetron PONV Prevention Study Group.
    Diemunsch P, Korttila K, Leeser J, Helmers JH, Wilkey B, Navé S, Radke AJ, Hahne WF, Brown RA.
    J Clin Anesth; 1998 Mar; 10(2):145-52. PubMed ID: 9524901
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients.
    Bey P, Wilkinson PM, Resbeut M, Bourdin S, Le Floch O, Hahne W, Claverie N.
    Support Care Cancer; 1996 Sep; 4(5):378-83. PubMed ID: 8883232
    [Abstract] [Full Text] [Related]

  • 7. Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting.
    Diemunsch P, Leeser J, Feiss P, D'Hollander A, Bradburn BG, Paxton D, Whitmore J, Panouillot P, Navé S, Brown RA, Hahne WF.
    Can J Anaesth; 1997 Feb; 44(2):173-81. PubMed ID: 9043731
    [Abstract] [Full Text] [Related]

  • 8. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
    Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C.
    J Clin Oncol; 1997 Aug; 15(8):2966-73. PubMed ID: 9256141
    [Abstract] [Full Text] [Related]

  • 9. Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group.
    Kovac AL, Scuderi PE, Boerner TF, Chelly JE, Goldberg ME, Hantler CB, Hahne WF, Brown RA.
    Anesth Analg; 1997 Sep; 85(3):546-52. PubMed ID: 9296407
    [Abstract] [Full Text] [Related]

  • 10. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
    Chevallier B, Cappelaere P, Splinter T, Fabbro M, Wendling JL, Cals L, Catimel G, Giovannini M, Khayat D, Bastit P, Claverie N.
    Support Care Cancer; 1997 Jan; 5(1):22-30. PubMed ID: 9010986
    [Abstract] [Full Text] [Related]

  • 11. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B, Cappelaere P, Martin M, Cervantes A, Fabbro M, Rivière A, Khayat D, Bleiberg H, Faraldi M, Claverie N, Aranda E, Auclerc G, Audhuy B, Benhammouda A, Bleiberg H, Cals L, Cappelaere P, Cattan A, Cervantes A, Chevallier B, Conroy T, Cupissol D, De Grève J, Diaz-Rubio E, Seitz JF.
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of single-dose intravenous dolasetron versus ondansetron in the prevention of postoperative nausea and vomiting.
    Walker JB.
    Clin Ther; 2001 Jun; 23(6):932-8. PubMed ID: 11440292
    [Abstract] [Full Text] [Related]

  • 13. Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery.
    Graczyk SG, McKenzie R, Kallar S, Hickok CB, Melson T, Morrill B, Hahne WF, Brown RA.
    Anesth Analg; 1997 Feb; 84(2):325-30. PubMed ID: 9024022
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
    Fauser AA, Duclos B, Chemaissani A, Del Favero A, Cognetti F, Diaz-Rubio E, Cortes-Funes H, Conte PF, Dressler H.
    Eur J Cancer; 1996 Aug; 32A(9):1523-9. PubMed ID: 8911112
    [Abstract] [Full Text] [Related]

  • 15. Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy. The Canadian Dolasetron Study Group.
    Warriner CB, Knox D, Belo S, Cole C, Finegan BA, Perreault L.
    Can J Anaesth; 1997 Nov; 44(11):1167-73. PubMed ID: 9398956
    [Abstract] [Full Text] [Related]

  • 16. Timing of administration of dolasetron affects dose necessary to prevent postoperative nausea and vomiting.
    Korttila KT, Jokinen JD.
    J Clin Anesth; 2004 Aug; 16(5):364-70. PubMed ID: 15374558
    [Abstract] [Full Text] [Related]

  • 17. A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups.
    Fortney JT, Gan TJ, Graczyk S, Wetchler B, Melson T, Khalil S, McKenzie R, Parrillo S, Glass PS, Moote C, Wermeling D, Parasuraman TV, Duncan B, Creed MR.
    Anesth Analg; 1998 Apr; 86(4):731-8. PubMed ID: 9539593
    [Abstract] [Full Text] [Related]

  • 18. Postoperative nausea and vomiting after surgery for prognathism: not only a question of patients' comfort. A placebo-controlled comparison of dolasetron and droperidol.
    Piper SN, Röhm K, Boldt J, Kranke P, Maleck W, Seifert R, Suttner S.
    J Craniomaxillofac Surg; 2008 Apr; 36(3):173-179. PubMed ID: 18353666
    [Abstract] [Full Text] [Related]

  • 19. Dolasetron for the prevention of postoperative nausea and vomiting following outpatient surgery with general anaesthesia: a randomized, placebo-controlled study. The Dolasetron PONV Prevention Study Group.
    Philip BK, Pearman MH, Kovac AL, Chelly JE, Wetchler BV, McKenzie R, Monk TG, Dershwitz M, Mingus M, Sung YF, Hahne WF, Brown RA.
    Eur J Anaesthesiol; 2000 Jan; 17(1):23-32. PubMed ID: 10758440
    [Abstract] [Full Text] [Related]

  • 20. A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis.
    Zarate E, Watcha MF, White PF, Klein KW, Sa Rego M, Stewart DG.
    Anesth Analg; 2000 Jun; 90(6):1352-8. PubMed ID: 10825320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.